Iran's GLP-1 Cost-Effectiveness Model

A new Iranian decision-model analysis compared tirzepatide, semaglutide, and liraglutide for adults with overweight or obesity who did not have diabetes. Over its 68-week horizon, the model found semaglutide cost-effective at the Iranian threshold it used. Tirzepatide produced more estimated health benefit, but at a higher cost that yielded an incremental cost-effectiveness ratio of US$34,423.89 per quality-adjusted life year (QALY) versus semaglutide. Liraglutide was dominated by semaglutide in the model^[1].

That is a result about one payer perspective, one set of inputs, and one short time horizon. It is not evidence that one medicine is the right choice for an individual, and it does not compare these medicines in a new clinical trial. The paper itself is a cost-effectiveness analysis, not a treatment recommendation.

What the Iranian model assessed

The authors built a decision-tree model from the Iranian payer perspective. They modelled adults aged 18 years or older with a BMI of at least 30 kg/m², or at least 27 kg/m² plus one weight-related complication, while excluding people with diabetes. The stated time horizon was 68 weeks^[1].

Its effectiveness and safety inputs, including treatment discontinuation, came from published literature rather than from a head-to-head Iranian trial. The model translated BMI change and adverse-event-related disutility into QALYs, then included drug-acquisition and adverse-event-management costs. The authors also reported deterministic and probabilistic sensitivity analyses^[1].

A QALY is a health-economic outcome that combines estimated length and quality of life. It is useful for comparing modelled value across options, but it is not a direct measure of kilograms lost, symptoms, safety for a particular person, or real-world affordability. The reported result depends on the model assumptions and the price and threshold used in the Iranian analysis.

The reported results

Compared with semaglutide, tirzepatide generated greater estimated health benefits at higher cost. The authors reported the resulting incremental ratio as US$34,423.89 per QALY. They also reported liraglutide as dominated by semaglutide, a technical term meaning that semaglutide was modelled as both less costly and more effective in that comparison^[1].

The paper used an Iranian willingness-to-pay threshold of PPP US$15,558.5 per QALY, described as one times GDP per capita in 2026. Against that threshold, the authors concluded that semaglutide was cost-effective, whereas tirzepatide's higher price limited its cost-effectiveness at the prices represented in their model^[1].

Those labels should not be exported unaltered to another country. A cost-effectiveness threshold is a policy input, and medicine prices, reimbursement rules, negotiated discounts, and healthcare costs can differ substantially between systems. The article does not establish what an insurer, public health service, or patient will pay outside the specific Iranian model.

What the paper does and does not compare

The clinical question is narrower than it may first appear. It compares model outputs for injectable medicines in adults without diabetes, not direct clinical outcomes between all three treatments in a single trial. The underlying paper identifies tirzepatide, semaglutide, and liraglutide as the modelled interventions, but its abstract does not provide enough detail to treat the analysis as a direct comparative efficacy trial^[1].

The drugs also have different regulatory labels and availability by jurisdiction. Readers looking for background on the medicines can consult our tirzepatide reference page, semaglutide reference page, and liraglutide. Those pages are context, not a substitute for current local prescribing information or clinical advice.

Why the short horizon matters

The 68-week horizon captures a limited period of treatment and modelled outcomes. It cannot, by itself, settle what happens with longer-term persistence, changes in price, discontinuation outside the source studies, later healthcare use, or outcomes after treatment stops. The abstract reports sensitivity analyses, but it does not expose enough detail to judge every assumption or scenario from the PubMed record alone^[1].

The publisher's article page confirms the same basic methods and results, including the payer perspective, direct medical cost categories, and the reported ratio. Its accessible abstract does not change the key boundary: this is an economic model using published inputs, not new evidence of individual clinical benefit or harm^[2].

What we don't yet know

This paper does not answer which treatment a particular person should use, whether its conclusion would hold under another country's prices and coverage rules, or how the model would perform over several years. It also cannot replace direct, adequately comparable clinical evidence. Economic evaluations can inform resource-allocation discussions; they do not prescribe care. Its result should remain attached to the stated Iranian payer perspective.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.